Specifications TableSubjectEconomics and EconometricsSpecific subject areaCost-effectiveness analysisType of dataTablesHow data were acquiredData were obtained from clinical trials, published literature and Taiwanese National Health Insurance Administration\'s website.Data formatRaw and analyzed dataParameters for data collectionData were obtained for metastatic breast cancer patients in the Taiwanese setting.Description of data collectionCost data were mostly obtained from the Taiwanese National Health Insurance Administration website and further calculated based on average weight and body surface area for Taiwanese females. Transition probabilities were estimated following a survival analysis of approximated individual patient data from published Kaplan-Meier survival curves of clinical trials. Utilities were obtained from published literature.Data source locationTaiwan and literatureData accessibilityData were included in this articleRelated research articleA cost-effectiveness analysis of Trastuzumab-Containing Treatment Sequences for HER-2 Positive Metastatic Breast Cancer Patients in Taiwan. *The Breast (Revision submitted).***Value of the Data**•Our data provide input parameters for cost, utilities and transition probabilities for cost-effectiveness analysis (CEA) of Trastuzumab-based regimens for metastatic breast cancer patients in Taiwan.•Researchers conducting economic evaluation including cost-effectiveness analysis and cost of illness studies for metastatic breast cancer patients would benefit from these data.•Parenteral drug costs provided in this article are adjusted for wastage through a scenario analysis.

1. Data {#sec1}
=======

The dataset includes the model input parameters for a Markov model assessing the cost-effectiveness of four trastuzumab containing sequences for HER-2 positive metastatic breast cancer patients as well as a brief description of the model assumptions. These input parameters include cost, transition probabilities, and utilities. Cost data include physician visit fee ([Table 1](#tbl1){ref-type="table"}), treatment acquisition cost both considering or not considering drug wastage ([Table 2](#tbl2){ref-type="table"}), costs associated with adverse event management ([Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}), costs for computed tomography (CT) scan and echocardiogram and laboratory costs ([Table 4](#tbl4){ref-type="table"}). For transition probabilities, the shape and scale parameters for progression-free survival and overall survival were estimated as well as the probability of developing adverse events while on different treatment regimens. The entire list of model input parameters including the lower and higher bounds for deterministic sensitivity analysis as well as the distribution and standard deviations for probabilistic sensitivity analyses are shown in [Table 5](#tbl5){ref-type="table"}, [Table 6](#tbl6){ref-type="table"} for base case and no drug wastage scenarios respectively.Table 1Physician visit costs and treatment acquisition costs.Table 1Input parameters - CostsAssumption and cost calculationMonthly cost for physician visit▪Cost for physician visit = \$8.15 \[[@bib1]\]▪Visit every 3 weeks or every 0.69 months▪8.15\*0.69 = 4.348125Base case scenarioAcquisition cost of treatments--- Pertuzumab, Docetaxel, Trastuzumab \[PTH\] vs. Docetaxel/Trastuzumab \[TH\] \[[@bib2]\]▪Assumption: Patients received a maximum of 6 cycles of docetaxel. Trastuzumab/pertuzumab alone was continued to avoid neuropathy in case patients responded to treatments.▪Drug Costs (per unit) were Average Sale Prices (ASP) from National Health Insurance Administration Ministry of Health and Welfare (March 2017) \[[@bib3],[@bib4]\]▪Cost of docetaxel: 40mg/ml 0.5ml vial, \$132.68; 40mg/ml 2ml vial, \$500.50; 75 mg/m2, assuming body surface area (BSA) of 1.59 = 119.25 mg = 1 vial 40mg/ml 2ml + 2x 40mg/ml 0.5ml = \$765.86▪Cost of Trastuzumab: 440 mg vial, \$1852.07; Day 1 Cycle 1 is 8 mg/kg, which would be 464.8 mg = 2 × 440mg = \$3704.14 for an average person weighing 58.1 Kg; Subsequent cycles 6 mg/kg which would be 348.6 mg = 1 × 440 mg = \$1852.07 for an average person weighing 58.1 Kg▪Cost of pertuzumab: 420 mg, \$2282.21; Initial cycle 1 dose is 840 mg, or \$4564.42; Subsequent doses are 420 mg or \$2282.21▪Cost of Pegfilgrastim: 6mg, \$662.68 per cycle cost for 6 cycles▪**Total weekly cost of Pertuzumab, Trastuzumab, Docetaxel \[THP\], plus pegfilgrastim**: week 1: \$9697.10 = \$765.86+\$3704.14+\$4564.42+\$662.68weeks 4,7,10,13,16: \$5562.82 = \$765.86+\$1852.07+\$2282.21+\$662.68weeks 17,20,23,26, 29, and beyond (no docetaxel): \$4134.28 = \$1852.07+\$2282.21▪**Total weekly cost of Trastuzumab, Docetaxel \[TH\], no pegfilgrastim:** week 1: \$4470.00 = \$765.86+\$3704.14weeks 4,7,10,13,16: \$2617.93 = \$765.86+\$1852.07weeks 17,20,23,26, 29, and beyond (no docetaxel): \$1852.07Acquisition cost of treatments---\
Trastuzumab emtansine (TDM-1)▪Assumption: patient received TDM-1 every 3 weeks▪Drug Costs (per unit) were Average Sale Prices (ASP) from National Health Insurance Administration Ministry of Health and Welfare (March 2017) \[[@bib3],[@bib4]\]▪Cost of TDM-1: 10 mg, \$1794.71; 160 mg, \$2871.77; dose is 3.6 mg/kg which is 209.16 mg for an average person weighing 58.1 Kg; 1 × 160mg + 1 × 100 mg; \$4666.48 every 21 days▪**Total cost of TDM-1 (every 3 weeks): \$4666.48**Acquisition cost of treatments---\
Lapatinib + Capecitabine (Xeloda)▪Drug Costs (per unit) were Average Sale Prices (ASP) from National Health Insurance Administration Ministry of Health and Welfare (March 2017) \[[@bib3],[@bib4]\]▪Cost of Lapatinib: 1500 mg, \$97.74 (daily); weekly cost of lapatinib is \$684.18▪Cost of Capecitabine: 500 mg, \$3.23; dose is 2000 mg/m2 daily which is 3180 mg or 7 tablets daily for an average person with BSA of 1.59; \$22.61 per day; x14 days on with 1 week rest; weekly cost of capecitabine is \$158.27 (\$22.61x7), assuming 2 weeks of treatment per cycle▪**Total cost of Lapatinib + Capecitabine:**Weeks 1 and 2, weekly cost is: \$842.45=(\$684.18 + 158.27)Week 3 weekly cost is: \$684.18Week 4, weekly cost is: \$842.45=(\$684.18 + 158.27)Acquisition cost of treatments---\
Trastuzumab + Lapatinib▪Drug Costs (per unit) were Average Sale Prices (ASP) from National Health Insurance Administration Ministry of Health and Welfare (March 2017) \[[@bib3],[@bib4]\]▪Cost of Trastuzumab: Loading Dose trastuzumab 8 mg/kg which is 464.8 mg for an average person weighing 58.1kg; 2 × 440mg; \$3704.14; Maintenance dose trastuzumab 6 mg/kg which is 348.6 mg for an average person weighing 58.1kg; 1 × 440 mg every 3 weeks; \$1852.07▪Cost of Lapatinib: 1500 mg, \$97.74 (daily); weekly cost of lapatinib is \$684.18▪**Total cost of Trastuzumab + Lapatinib:**Week 1: \$4388.32 = \$3704.14+\$684.18Week 2,3: \$684.18Week 4: \$2536.25 = \$1852.07+\$684.18Week 5,6: \$684.18Week 7,10,13,16, etc: \$2536.25Week 8,9,11,12,14,15,17,18, etc.: \$684.18Acquisition cost of treatments---Trastuzumab + Capecitabine▪Drug Costs (per unit) were Average Sale Prices (ASP) from National Health Insurance Administration Ministry of Health and Welfare (March 2017) \[[@bib3],[@bib4]\]▪Cost of Trastuzumab: Loading Dose trastuzumab 8 mg/kg which is 464.8 mg for an average person weighing 58.1kg; 2 × 440mg; \$3704.14; Maintenance dose trastuzumab 6 mg/kg which is 348.6 mg for an average person weighing 58.1kg; 1 × 440 mg every 3 weeks; \$1852.07▪Cost of Capecitabine: 500 mg, \$3.23; dose is 2000 mg/m2 daily which is 3180 mg or 7 tablets daily for an average person with BSA of 1.59; \$22.61 per day; x14 days on with 1 week rest; weekly cost of capecitabine is \$158.27 (\$22.61x7), assuming 2 weeks of treatment per cycle▪**Total cost of Trastuzumab + Capecitabine:**Week 1: \$3862.41 = \$3704.14+\$158.27Week 2: \$158.27Week 3: \$3704.14Week 4: \$2010.34 = \$1852.07+\$158.27Week 5: \$158.27Week 6: \$3704.14Week 7: \$2010.34 = \$1852.07+\$158.27Week 8: \$158.27Week 9: \$3704.14Weeks 10, 13, 16, 19, 22, etc...: \$2010.34 = \$1852.07+\$158.27Weeks 11,14,17,20,23, etc...:\$158.27Weeks 12,15,18,21,24, etc...:\$3704.14No drug wastage scenarioAcquisition cost of treatments--- Pertuzumab, Docetaxel, Trastuzumab \[PTH\] vs. Docetaxel/Trastuzumab \[TH\] \[[@bib2]\]▪Assumption: Patients received a maximum of 6 cycles of docetaxel, and then if they were responding trastuzumab/pertuzumab alone was continued to avoid neuropathy.▪Drug Costs (per unit) were Average Sale Prices (ASP) from National Health Insurance Administration Ministry of Health and Welfare (March 2017) \[[@bib3],[@bib4]\]▪Cost of docetaxel: 40mg/ml 0.5ml vial, \$132.68; 40mg/ml 2ml vial, \$500.50; 75 mg/m2, assuming body surface area (BSA) of 1.59 = 119.25 mg = 1.49 vial 40mg/ml 2ml = \$760.88▪Cost of trastuzumab: 440 mg vial, \$1852.07; Day 1 Cycle 1 is 8 mg/kg, which would be 464.8 mg = 1.056 vials = \$1955.79 for an average person weighing 58.1 Kg; Subsequent cycles 6 mg/kg which would be 348.6 mg = 0.792 vials = \$1466.84 for an average person weighing 58.1 Kg▪Cost of pertuzumab: 420 mg, \$2282.21; Initial cycle 1 dose is 840 mg, or \$4564.42; Subsequent doses are 420 mg or \$2282.21▪Cost of Pegfilgrastim: 6mg, \$662.68 per cycle cost for 6 cycles▪**Total weekly cost of Pertuzumab, Trastuzumab, Docetaxel \[THP\], plus pegfilgrastim:** week 1: \$7,943,77 = \$760.88+\$1955.79+\$4564.42+\$662.68weeks 4,7,10,13,16: \$5172.61 = \$760.88+\$1466.84+\$2282.21+\$662.68weeks 17,20,23,26, 29, and beyond (no docetaxel): \$3749.05 = \$1466.84+\$2282.21▪**Total weekly cost of Trastuzumab, Docetaxel \[TH\], no pegfilgrastim:**week 1: \$2716.67 = \$760.88+\$1955.79weeks 4,7,10,13,16: \$2227.72 = \$760.88+\$1466.84weeks 17,20,23,26, 29, and beyond (no docetaxel): \$1466.84Acquisition cost of treatments---Trastuzumab emtansine (TDM-1)▪Drug Costs (per unit) were Average Sale Prices (ASP) from National Health Insurance Administration Ministry of Health and Welfare (March 2017) \[[@bib3],[@bib4]\]▪Assumption: patient received TDM-1 every 3 weeks▪Cost of TDM-1: 10 mg, \$1794.71; 160 mg, \$2871.77; dose is 3.6 mg/kg which is 209.16 mg for an average person weighing 58.1 Kg; 1 × 160mg + 0.4915 × 100mg; \$3754.05 every 21 days▪**Total cost of TDM-1 (every 3 weeks): \$3754.05**Acquisition cost of treatments---\
Lapatinib + Capecitabine (Xeloda)▪Drug Costs (per unit) were Average Sale Prices (ASP) from National Health Insurance Administration Ministry of Health and Welfare (March 2017) \[[@bib3],[@bib4]\]▪Cost of Lapatinib: 1500 mg, \$97.74 (daily); weekly cost of lapatinib is \$684.18▪Cost of Capecitabine: 500 mg, \$3.23; dose is 2000 mg/m2 daily which is 3180 mg or 7 tablets daily for an average person with BSA of 1.59; \$22.61 per day; x14 days on with 1 week rest; weekly cost of capecitabine is \$158.27 (\$22.61x7), assuming 2 weeks of treatment per cycle▪**Total cost of Lapatinib + Capecitabine:**Weeks 1 and 2, weekly cost is: \$842.45=(\$684.18 + 158.27)Week 3 weekly cost is: \$684.18\<Week 4, weekly cost is: \$842.45=(\$684.18 + 158.27)Acquisition cost of treatments---\
Trastuzumab + Lapatinib▪Drug Costs (per unit) were Average Sale Prices (ASP) from National Health Insurance Administration Ministry of Health and Welfare (March 2017) \[[@bib3],[@bib4]\]▪Cost of Trastuzumab: Loading Dose trastuzumab 8 mg/kg which is 464.8 mg for an average person weighing 58.1kg; 1.056 × 440mg; \$1955.79; Maintenance dose trastuzumab 6 mg/kg which is 348.6 mg for an average person weighing 58.1kg; 0.792 × 440 mg every 3 weeks; \$1466.84▪Cost of Lapatinib: 1500 mg, \$97.74 (daily); weekly cost of lapatinib is \$684.18▪Total cost of Trastuzumab + Lapatinib:Week 1: \$2639.97 = \$1955.79+\$684.18Week 2,3: \$684.18Week 4: \$2151.02 = \$1466.84+\$684.18Week 5,6: \$684.18Week 7,10,13,16, etc: \$2151.02Week 8,9,11,12,14,15,17,18, etc.: \$684.18Acquisition cost of treatments---Trastuzumab + Capecitabine▪Drug Costs (per unit) were Average Sale Prices (ASP) from National Health Insurance Administration Ministry of Health and Welfare (March 2017) \[[@bib3],[@bib4]\]▪Cost of Trastuzumab: Loading Dose trastuzumab 8 mg/kg which is 464.8 mg for an average person weighing 58.1kg; 1.056 × 440mg; \$1955.79▪Maintenance dose trastuzumab 6 mg/kg which is 348.6 mg for an average person weighing 58.1kg; 0.792 × 440 mg every 3 weeks; \$1466.84▪Cost of Capecitabine: 500 mg, \$3.23; dose is 2000 mg/m2 daily which is 3180 mg or 7 tablets daily for an average person with BSA of 1.59; \$22.61 per day; x14 days on with 1 week rest; weekly cost of capecitabine is \$158.27 (\$22.61x7), assuming 2 weeks of treatment per cycle▪**Total cost of Trastuzumab + Capecitabine:**Week 1: \$2114.06 = \$1955.79+\$158.27Week 2: \$158.27Week 3: \$1955.79Week 4: \$1625.11 = \$1466.84+\$158.27\<Week 5: \$158.27Week 6: \$1955.79Week 7: \$1625.11 = \$1466.84+\$158.27\<Week 8: \$158.27Week 9: \$1955.79Weeks 10, 13, 16, 19, 22, etc...: \$1625.11 = \$1466.84+\$158.27Weeks 11,14,17,20,23, etc...:\$158.27Weeks 12,15,18,21,24, etc...:\$1955.79Table 2Cost associated with adverse event management.Table 2Adverse eventsCosts in 2018 USDReferenceAverageLower boundUpper boundDiarrhea3586.311766.397172.62Niraula et al. \[[@bib5]\]Neutropenia6904.983532.7818038.6Niraula et al. \[[@bib5]\]Febrile neutropenia22481.3411240.6746033.23Niraula et al. \[[@bib5]\]Thrombocytopenia18199.189046.0635863.1Niraula et al. \[[@bib5]\]Hand-foot syndrome/Palmar--plantar erythrodysesthesia/skin changes2034.031017.014121.58Niraula et al. \[[@bib5]\]Rash321.16160.58535.27Niraula et al. \[[@bib5]\]Nausea/Vomiting6958.513479.2613917.02Niraula et al. \[[@bib5]\]Fatigue1017.01535.27909.96Niraula et al. \[[@bib5]\]Dyspnea4720.63----Sharpe \[[@bib6]\]Cardiovascular disorder2410.241826.864871.63Garrison et al. \[[@bib7]\][^1]Table 3Estimated per-patient cost (2018 US dollars)[a](#tbl3fna){ref-type="table-fn"}of managing treatment-related grade 3 and above adverse events that occurred in ≥ 5% of patients.Table 3Adverse eventPertuzumab + Trastuzumab + DocetaxelTrastuzumab + DocetaxelTDM1Lapatinib + CapecitabineTrastuzumab + LapatinibTrastuzumab + CapecitabineTrialSwain et al. \[[@bib2]\]Swain et al. \[[@bib2]\]Verma et al. \[[@bib8]\]Geyer et al. \[[@bib9]\]Blackwell et al. \[[@bib10]\]von Minckwitz et al. \[[@bib11]\]Diarrhea322.76 (158.97; 645.53)----459.05 (226.10; 918.10)251.05 (123.65; 502.09)191.15 (94.15; 382.30)Neutropenia3383.44 (1731.06; 8838.92)3176.29 (1625.08; 8297.75)--------Febrile neutropenia2922.58 (1461.29; 5984.33)1573.69 (786.85; 3222.32)--------Thrombocytopenia----2347.69 (1166.94; 4626.34)------Hand-foot syndrome/Palmar--plantar erythrodysesthesia/skin changes------142.38 (71.19; 288.50)--660.44 (330.22; 1338.27)Rash--------70.65 (35.32; 117.76)--Nausea/Vomiting------------Fatigue------------Dyspnea------------Cardiovascular disorder----------125.09 (94.82; 252.83)Total6628.78 (3351.33; 115468.77)4749.98 (2411.92; 11520.08)2347.69 (1166.94; 4626.34)601.43 (297.29: 1206.61)321.70 (158.98; 619.85)976.68 (519.18; 1973.40)[^2]Table 4Costs and assumptions for computed tomography (CT) scan, laboratory tests, echocardiogram.Table 4Cost input parameterAssumption and cost calculationComputed tomography (CT) scan \[[@bib1]\]▪Assumption: CT scan every 2 months or 8.69625 weeks▪Reimbursement item code of National Health Insurance: 33071B CT thorax/abdomen/pelvis (\$142.86)▪**Cost of CT scan (every 9 weeks):** \$142.86Laboratory tests \[[@bib1]\]▪Assumption: Every three weeks or 0.69 months▪Comprehensive metabolic panel (\$15.71); Complete blood count (\$6.27)▪**Cost of blood tests (every three weeks):** \$22.98Echocardiogram \[[@bib1]\]▪Assumption: Only for patients receiving HER2 therapy, every 3 months or 13.044 weeks▪Echocardiography, transthoracic, real-time with image documentation (\$99.52)▪**Cost of an echocardiogram (every 13 weeks):** \$99.52Table 5Model input parameters for base case scenario.Table 5ParametersUnitBaselineDeterministic SAProbabilistic SAAssumptionsLowHighPSA (SD)DistributionMedical visitPhysician feesEvery 3 weeks8.156.1110.191.01875Gamma25% +/− ruleAcquisition cost of treatmentsLoading dose pertuzumab (840 mg)1st week of treatment only4564.422282.216846.631141.105Gamma50% +/− ruleMaintenance dose pertuzumab (420 mg)Every 3 weeks starting from week 42282.211141.113423.32570.5525Gamma50% +/− ruleLoading dose trastuzumab (8mg/kg) -1st week of treatment only3704.141852.075556.21926.035Gamma50% +/− ruleMaintenance dose trastuzumab (6 mg/kg)Every 3 weeks starting from week 41852.07926.042778.11463.0175Gamma50% +/− ruleDocetaxel (1 mg)Every 3 weeks for 6 cycles765.86382.931148.79191.465Gamma50% +/− rulePegfilgrastim (6 mg)Every 3 weeks for 6 cycles662.68331.34994.02165.67Gamma50% +/− ruleTDM1Every 3 weeks4666.482333.246999.721166.62Gamma50% +/− ruleCapecitabine (500 mg)Assuming 2 weeks of treatment per cycle + 1 week rest158.2779.14237.4139.5675Gamma50% +/− ruleLapatinib (1500 mg daily)Weekly684.18342.091026.27171.045Gamma50% +/− ruleCost of the management of Adverse Events (grade 3/4)Pertuzumab + trastuzumab + docetaxel1 time6628.7843351.32515468.7743029.362GammaCalculatedTrastuzumab + docetaxel1 time4749.9822411.92411520.0752277.038GammaCalculatedT-DM11 time2347.6951166.9424626.3412864.8498GammaCalculatedLapatinib + capecitabine1 time601.4326297.291160.6912215.8503GammaCalculatedTrastuzumab + lapatinib1 time321.70158.9764619.84961115.2183GammaCalculatedTrastuzumab + capecitabine1 time976.6843519.18151954.2796358.7745GammaCalculatedCost of Computed tomography (CT) scanEvery 9 weeks142.8571107.1429178.5714317.85714Gamma25% +/− ruleLaboratory testsCost of blood workEvery 3 weeks6.274.70257.83750.78375Gamma25% +/− ruleCost of echocardiogramEvery 13 weeks119.0589.2875148.812514.88125Gamma25% +/− ruleCost of palliative care/End of life1 time7185.7213592.8610778.5811796.43Gamma50% +/− ruleUtilitiesProgression-free under treatment0.7857460.4844780.93468890.112553BetaCalculatedTreatment response0.0610.0252150.07424490.012257BetaCalculatedDisease progression under treatment0.5380.1959370.84753890.162901BetaCalculatedDisutilitiesDisease progression−0.248−0.28854−0.0871499−0.050348UniformCalculatedAdverse events for pertuzumab + trastuzumab + docetaxel−0.05553−0.09841−0.0156854−0.02068UniformCalculatedAdverse events for trastuzumab + docetaxel−0.03953−0.05795−0.0112224−0.011682UniformCalculatedAdverse events for TDM1−0.00851−0.01246−0.0024128−0.002512UniformCalculatedAdverse events for lapatinib + capecitabine−0.01826−0.03193−0.00395−0.006996UniformCalculatedAdverse events for trastuzumab + lapatinib−0.01716−0.02629−0.00425−0.005509UniformCalculatedAdverse events for trastuzumab + capecitabine−0.04017−0.0747−0.0092301−0.016367Negative Beta/UniformCalculatedShape and scale parametersOS shape (Gamma)OS shape for pertuzumab + trastuzumab + Docetaxel0.5436960.4604370.64201120.09264GammaRegressionOS shape for trastuzumab + docetaxel0.5765010.5011510.66318020.082668GammaRegressionOS shape for TDM10.4743330.4141680.54323910.065853GammaRegressionOS shape for lapatinib + capecitabine0.4647840.3567330.6055610.126953GammaRegressionOS shape for trastuzumab + lapatinib0.5882670.4679060.73958810.138613GammaRegressionOS shape for trastuzumab + capecitabine0.4513020.338170.60228250.134751GammaRegressionOS scale (Lambda)OS scale for pertuzumab + trastuzumab + docetaxel0.0192410.0164470.02251070.003094GammaRegressionOS scale for trastuzumab + docetaxel0.0249960.0219420.0284760.003334GammaRegressionOS scale for TDM10.0325570.0290430.03649460.003802GammaRegressionOS scale for lapatinib + capecitabine0.0159810.01260.02026860.003912GammaRegressionOS scale for trastuzumab + lapatinib0.0189850.0152580.02362320.004268GammaRegressionOS scale for trastuzumab + capecitabine0.0409660.0329840.05088120.009131GammaRegressionPFS shape (Gamma)PFS shape for pertuzumab + trastuzumab + docetaxel0.6218720.5605430.68991120.066004GammaRegressionOS shape (Gamma)OS shape for pertuzumab + trastuzumab + Docetaxel0.5436960.4604370.64201120.09264GammaRegressionOS shape for trastuzumab + docetaxel0.5765010.5011510.66318020.082668GammaRegressionOS shape for TDM10.4743330.4141680.54323910.065853GammaRegressionOS shape for lapatinib + capecitabine0.4647840.3567330.6055610.126953GammaRegressionOS shape for trastuzumab + lapatinib0.5882670.4679060.73958810.138613GammaRegressionOS shape for trastuzumab + capecitabine0.4513020.338170.60228250.134751GammaRegressionOS scale (Lambda)OS scale for pertuzumab + trastuzumab + docetaxel0.0192410.0164470.02251070.003094GammaRegressionOS scale for trastuzumab + docetaxel0.0249960.0219420.0284760.003334GammaRegressionOS scale for TDM10.0325570.0290430.03649460.003802GammaRegressionOS scale for lapatinib + capecitabine0.0159810.01260.02026860.003912GammaRegressionOS scale for trastuzumab + lapatinib0.0189850.0152580.02362320.004268GammaRegressionOS scale for trastuzumab + capecitabine0.0409660.0329840.05088120.009131GammaRegressionPFS shape for trastuzumab + docetaxel0.5553810.5044060.61150740.054643GammaRegressionPFS shape for TDM10.6106110.552050.67538280.062925GammaRegressionPFS shape for lapatinib + capecitabine0.5161630.4228770.63002730.105689GammaRegressionPFS shape for trastuzumab + Lapatinib0.5538420.4808210.6379520.080169GammaRegressionPFS shape for trastuzumab + capecitabine0.5083970.4102620.63000550.112114GammaRegressionPFS scale (Lambda)PFS scale for pertuzumab + trastuzumab + docetaxel0.0520510.0465270.05823040.005971GammaRegressionPFS scale for trastuzumab + docetaxel0.0741280.0672340.0817290.007396GammaRegressionPFS scale for TDM10.1042560.0932960.1165040.011841GammaRegressionPFS scale for lapatinib + capecitabine0.033890.0279660.04106950.006685GammaRegressionPFS scale for trastuzumab + lapatinib0.0823150.0699290.09689320.013757GammaRegressionPFS scale for trastuzumab + capecitabine0.1151860.0937030.14159510.024435GammaRegressionWeekly probability of developing adverse eventsPertuzumab + trastuzumab + docetaxel0.0025640.0012820.00384660.000641BetaCalculatedTrastuzumab + docetaxel0.0019690.0009840.00295280.000492BetaCalculatedTDM10.0040390.002020.00605910.00101BetaCalculatedLapatinib + capecitabine0.01050.005250.01575060.002625BetaCalculatedTrastuzumab + Lapatinib0.0019410.0009710.00291220.000485BetaCalculatedTrastuzumab + capecitabine0.0057660.0028830.00864930.001442BetaCalculatedDiscount rate -- weekly0.00066200.000939--UniformCalculatedTable 6Model input parameters for no drug wastage scenario.Table 6ParametersUnitBaselineDeterministic SAProbabilistic SAAssumptionsLowHighPSA (SD)DistributionMedical visitPhysician feesEvery 3 weeks8.156.1110.191.01875Gamma25% +/− ruleAcquisition cost of treatmentsLoading dose pertuzumab (840 mg)1st week of treatment only4564.422282.216846.631141.105Gamma50% +/− ruleMaintenance dose pertuzumab (420 mg)Every 3 weeks starting from week 42282.211141.113423.32570.5525Gamma50% +/− ruleLoading dose trastuzumab (8mg/kg) -1st week of treatment only1955.79977.892933.68488.9465Gamma50% +/− ruleMaintenance dose trastuzumab (6 mg/kg)Every 3 weeks starting from week 41466.84733.422200.26366.7099Gamma50% +/− ruleDocetaxel (1 mg)Every 3 weeks for 6 cycles760.88380.441141.33190.2211Gamma50% +/− rulePegfilgrastim (6 mg)Every 3 weeks for 6 cycles662.68331.34994.02165.67Gamma50% +/− ruleTDM1Every 3 weeks3754.051877.025631.07938.5124Gamma50% +/− ruleCapecitabine (500 mg)Assuming 2 weeks of treatment per cycle + 1 week rest158.2779.14237.4139.5675Gamma50% +/− ruleLapatinib (1500 mg daily)Weekly684.18342.091026.27171.045Gamma50% +/− ruleCost of the management of Adverse Events (grade 3/4)Pertuzumab + trastuzumab + docetaxel1 time6628.7843351.32515468.7743029.362GammaCalculatedTrastuzumab + docetaxel1 time4749.9822411.92411520.0752277.038GammaCalculatedT-DM11 time2347.6951166.9424626.3412864.8498GammaCalculatedLapatinib + capecitabine1 time601.4326297.291160.6912215.8503GammaCalculatedTrastuzumab + lapatinib1 time321.70158.9764619.84961115.2183GammaCalculatedTrastuzumab + capecitabine1 time976.6843519.18151954.2796358.7745GammaCalculatedCost of Computed tomography (CT) scanEvery 9 weeks142.8571107.1429178.5714317.85714Gamma25% +/− ruleLaboratory testsCost of blood workEvery 3 weeks6.274.70257.83750.78375Gamma25% +/− ruleCost of echocardiogramEvery 13 weeks119.0589.2875148.812514.88125Gamma25% +/− ruleCost of palliative care/End of life1 time7185.7213592.8610778.5811796.43Gamma50% +/− ruleUtilitiesProgression-free under treatment0.7857460.4844780.93468890.112553BetaCalculatedTreatment response0.0610.0252150.07424490.012257BetaCalculatedDisease progression under treatment0.5380.1959370.84753890.162901BetaCalculatedDisutilitiesDisease progression−0.248−0.28854−0.0871499−0.050348UniformCalculatedAdverse events for pertuzumab + trastuzumab + docetaxel−0.05553−0.09841−0.0156854−0.02068UniformCalculatedAdverse events for trastuzumab + docetaxel−0.03953−0.05795−0.0112224−0.011682UniformCalculatedAdverse events for TDM1−0.00851−0.01246−0.0024128−0.002512UniformCalculatedAdverse events for lapatinib + capecitabine−0.01826−0.03193−0.00395−0.006996UniformCalculatedAdverse events for trastuzumab + lapatinib−0.01716−0.02629−0.00425−0.005509UniformCalculatedAdverse events for trastuzumab + capecitabine−0.04017−0.0747−0.0092301−0.016367Negative Beta/UniformCalculatedShape and scale parametersOS shape (Gamma)OS shape for pertuzumab + trastuzumab + Docetaxel0.5436960.4604370.64201120.09264GammaRegressionOS shape for trastuzumab + docetaxel0.5765010.5011510.66318020.082668GammaRegressionOS shape for TDM10.4743330.4141680.54323910.065853GammaRegressionOS shape for lapatinib + capecitabine0.4647840.3567330.6055610.126953GammaRegressionOS shape for trastuzumab + lapatinib0.5882670.4679060.73958810.138613GammaRegressionOS shape for trastuzumab + capecitabine0.4513020.338170.60228250.134751GammaRegressionOS scale (Lambda)OS scale for pertuzumab + trastuzumab + docetaxel0.0192410.0164470.02251070.003094GammaRegressionOS scale for trastuzumab + docetaxel0.0249960.0219420.0284760.003334GammaRegressionOS scale for TDM10.0325570.0290430.03649460.003802GammaRegressionOS scale for lapatinib + capecitabine0.0159810.01260.02026860.003912GammaRegressionOS scale for trastuzumab + lapatinib0.0189850.0152580.02362320.004268GammaRegressionOS scale for trastuzumab + capecitabine0.0409660.0329840.05088120.009131GammaRegressionPFS shape (Gamma)rowheadPFS shape for pertuzumab + trastuzumab + docetaxel0.6218720.5605430.68991120.066004GammaRegressionPFS shape for trastuzumab + docetaxel0.5553810.5044060.61150740.054643GammaRegressionPFS shape for TDM10.6106110.552050.67538280.062925GammaRegressionPFS shape for lapatinib + capecitabine0.5161630.4228770.63002730.105689GammaRegressionPFS shape for trastuzumab + Lapatinib0.5538420.4808210.6379520.080169GammaRegressionPFS shape for trastuzumab + capecitabine0.5083970.4102620.63000550.112114GammaRegressionPFS scale (Lambda)PFS scale for pertuzumab + trastuzumab + docetaxel0.0520510.0465270.05823040.005971GammaRegressionPFS scale for trastuzumab + docetaxel0.0741280.0672340.0817290.007396GammaRegressionPFS scale for TDM10.1042560.0932960.1165040.011841GammaRegressionPFS scale for lapatinib + capecitabine0.033890.0279660.04106950.006685GammaRegressionPFS scale for trastuzumab + lapatinib0.0823150.0699290.09689320.013757GammaRegressionPFS scale for trastuzumab + capecitabine0.1151860.0937030.14159510.024435GammaRegressionWeekly probability of developing adverse eventsPertuzumab + trastuzumab + docetaxel0.0025640.0012820.00384660.000641BetaCalculatedTrastuzumab + docetaxel0.0019690.0009840.00295280.000492BetaCalculatedTDM10.0040390.002020.00605910.00101BetaCalculatedLapatinib + capecitabine0.01050.005250.01575060.002625BetaCalculatedTrastuzumab + Lapatinib0.0019410.0009710.00291220.000485BetaCalculatedTrastuzumab + capecitabine0.0057660.0028830.00864930.001442BetaCalculatedDiscount rate -- weekly0.00066200.000939--UniformCalculated

2. Experimental design, materials, and methods {#sec2}
==============================================

All costs presented were direct medical costs from the perspective of the Taiwanese National Health Insurance Administration (TNHIA). Cost for physician visits, treatments, CT scans, and laboratory tests were obtained from the website of TNHIA and personal communication. Most HER-2 targeted treatments are dosed based on weight or body surface area (BSA), so the treatment costs were then calculated based on the average height and weight for the Taiwanese female population. The average height and weight were obtained from the Ministry of Health and Welfare, Department of Statistics in Taiwan. Two cost strategies were developed---with drug wastage and without drug wastage. In the drug wastage scenario, the price per vial for each intravenous drug was not broken down. For example, the calculated dosage for docetaxel is 119.25 mg, the total costs for 1 vial of 80mg plus the cost for 2 vials of 20 mg which equals to 120 mg will represent the costs for 119.25.

mg docetaxel. However, in the no drug wastage scenario, the price per vial for each intravenous drug was broken down. For example, the calculated dosage for docetaxel is 119.25 mg and the costs for 1.49 vial of 80mg docetaxel will represent the costs for 119.25mg docetaxel. Cost of palliative care was obtained from Taiwanese National Health Insurance Research Database.

Transition probabilities for progression and mortality were obtained from published clinical trials. Individual patient data (IPD) were obtained from the PFS and OS Kaplan-Meier curves from these clinical trials using a method described previously. Five standard parametric distributions were fitted to the IPD: exponential, Weibull, Gompertz, lognormal, and log-logistic. The log-logistic model was then selected and used to reconstructed IPD and derived equations for transition probabilities using the shape and scale parameters of the fitted model because it had the greatest model fit which was evaluated based on AIC and BIC. Utilities were obtained from published literature and clinical trials.
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[^1]: \*Original costs were inflated to represent 2018 U.S. dollars costs using the Consumer Price Index (CPI) inflation calculator from the Bureau Labor of Statistics (available at <http://www.bls.gov/data/inflation_calculator.htm>)

[^2]: Original costs were inflated to represent 2018 U.S. dollars costs using the Consumer Price Index (CPI) inflation calculator from the Bureau Labor of Statistics (available at <http://www.bls.gov/data/inflation_calculator.htm>); Anorexia and headache were excluded based on clinical expert opinion; -: Adverse events occurred in less than 5% of patients.
